Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

265.79
+1.270.48%
Pre-market: 267.992.20+0.83%05:41 EDT
Volume:3.67M
Turnover:975.70M
Market Cap:469.75B
PE:75.09
High:266.91
Open:264.50
Low:263.03
Close:264.52
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.74
T/O Rate:0.21%
Dividend:6.83
Dividend Rate:2.57%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-79.15
PE(LYR):112.62

Loading ...

Regenxbio Q2 FY26 Swings to Net Income of $22.71 Million; Revenue Climbs to $108.02 Million

Reuters
·
Aug 06

AbbVie (ABBV) Gets a Buy from Berenberg Bank

TIPRANKS
·
Aug 06

AbbVie Prices USD 10 Billion Multi-Tranche Senior Notes Offering

Reuters
·
Aug 06

Leerink Partners Adjusts Price Target on AbbVie to $279 From $245

MT Newswires Live
·
Aug 05

Is AbbVie’s (ABBV) BOTOX Masseter Bet Quietly Rewriting Its Post-Humira Growth Story?

Simply Wall St.
·
Aug 05

Wall Street Warms to Healthcare Stocks as Tech Trade Faces Turbulence

Reuters
·
Aug 05

AbbVie upgraded to Buy from Hold at Erste Group

TIPRANKS
·
Aug 05

Abbvie : Leerink Partners Raises Target Price to $279 from $245

THOMSON REUTERS
·
Aug 05

Abbvie: Files for Nine-Part Notes of up to $10.0 Billion - SEC Filing

THOMSON REUTERS
·
Aug 05

Basilea Publishes Investor Presentation on Anti-Infectives Strategy, Pipeline and Hospital Brands Cresemba, Zevtera

Reuters
·
Aug 05

Market Chatter: AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition

MT Newswires Live
·
Aug 05

AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition, Bloomberg Reports

MT Newswires Live
·
Aug 05

Abbvie Seeks at Least $8 Billion in Debt to Fund Apogee Deal - Bloomberg News

THOMSON REUTERS
·
Aug 04

Abbvie Files for Nine-Part Senior Notes Offering; Size not Disclosed- SEC Filing

THOMSON REUTERS
·
Aug 04

Abbvie : Plans to Use Note Offering Proceeds for Apogee Therapeutics Acquisition Funding

THOMSON REUTERS
·
Aug 04

AbbVie Says FDA Accepts BOTOX Cosmetic sBLA for Masseter Muscle Prominence Indication

Reuters
·
Aug 04

Abbvie - Phase 3 Studies Met Primary Endpoints with Statistically Significant Improvements Versus Placebo

THOMSON REUTERS
·
Aug 04

Abbvie - Safety Profile Consistent with Established Uses; no New Safety Signals Identified

THOMSON REUTERS
·
Aug 04

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for Botox® Cosmetic for Masseter Muscle Prominence

THOMSON REUTERS
·
Aug 04

AbbVie price target raised to $288 from $261 at Guggenheim

TIPRANKS
·
Aug 04